Is there a new pathway relationship between melatonin and FEZ1 in experimental rat model of Alzheimer's disease?


Demir M., Yilmaz U. , Colak C., Cigremis Y. , Ozyalin F., Tekedereli I., ...Daha Fazla

BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, cilt.120, ss.70-77, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 120 Konu: 1
  • Basım Tarihi: 2019
  • Doi Numarası: 10.4149/bll_2019_011
  • Dergi Adı: BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY
  • Sayfa Sayıları: ss.70-77

Özet

Alzheimer's disease (AD) is a progressive neurodegenerative disease. This study was performed to determine the possible relationship between melatonin, which is known to play a role in the neuro-protective mechanism in AD, and fasciculation and elongation protein zeta 1 (FEZ1). Thirty male rats were included and separated into 3 groups (n = 10) as vehicle (artificial cerebrospinal fluid), streptozotocin (STZ) and STZ+melatonin (MLT). Two intracerebroventricular (icv) injections of 3 mg/kg STZ were made 48 hours apart. MLT injections were implemented for 14 days (ip; 10mg/kg/day). The Morris Water Maze (MWM) test was performed and rats were sacrificed to assess FEZ1 gene expression and protein levels from the hippocampus tissues and serum levels of noradrenaline (NA), dopamine and serotonin were determined from the blood samples. It was determined that the FEZ1/beta-actin protein ratio in the STZ group was significantly higher than that of the Vehicle group (p < 0.05) and in the MLT-administered group, the protein levels were decreased to the levels observed in the Vehicle group. Serum NA levels of STZ and STZ+MLT groups were found to be lower than those in the Vehicle group, while no difference was found regarding dopamine and serotonin levels.